公开(公告)号：WO2022069579A2

公开(公告)日：2022-04-07

申请号：PCT/EP2021/076848

申请日：2021-09-29

申请人： IMMATICS BIOTECHNOLOGIES GMBH

发明人： HUKELMANN, Jens ,  SCHUSTER, Heiko ,  WULLKOPF, Lena ,  SCHRÄDER, Christoph ,  FRITSCHE, Jens ,  KOWALEWSKI, Daniel ,  RÖMER, Michael ,  SCHOOR, Oliver

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K7/02 ,  C07K7/06 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  A61K2039/572 ,  A61K2039/804 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/828 ,  A61K2039/836 ,  A61K2039/844 ,  A61K2039/852 ,  A61K2039/86 ,  A61K2039/868 ,  A61K2039/876 ,  A61K2039/884 ,  A61K2039/892 ,  A61K39/0011 ,  C07K14/7051

摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：WO2022003568A1

公开(公告)日：2022-01-06

申请号：PCT/IB2021/055822

申请日：2021-06-29

申请人： DCPRIME B.V.

发明人： MANTING, Erik Hans ,  SINGH, Satwinder Kaur ,  ROVERS, Jeroen

IPC分类号： A61K39/00 ,  A61P35/00 ,  A61K2039/5154 ,  A61K2039/892 ,  A61K39/001129 ,  A61K39/001153 ,  A61K39/00117 ,  A61K39/00119

摘要： The present disclosure provides methods for treating a progressive ovarian cancer using an allogeneic leukemia-derived cell. Also provided are immunogenic compositions comprising an allogeneic leukemia-derived cell, and pharmaceutical compositions and formulations thereof.

公开(公告)号：WO2022238963A2

公开(公告)日：2022-11-17

申请号：PCT/IB2022/054447

申请日：2022-05-12

申请人： CRISPR THERAPEUTICS AG

发明人： TERRETT, Jonathan Alexander ,  DEQUEANT, Mary-Lee ,  WILL, Matthias

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C12N15/113 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/828 ,  A61K2039/852 ,  A61K2039/86 ,  A61K2039/868 ,  A61K2039/892 ,  A61K35/17 ,  A61K39/001138 ,  C07K14/7051 ,  C07K16/2803 ,  C07K16/2866 ,  C07K2319/03 ,  C12N15/1138 ,  C12N15/625 ,  C12N2310/20 ,  C12N5/0636

摘要： A method for treating a solid tumor (e.g., a CD70+ solid tumor) comprising one or more cycles of treatment, each cycle comprising administering to a human patient in need thereof an effective amount of a population of genetically engineered T cells after a lymphodepleting therapy, and optionally a treatment comprising an anti-CD38 antibody. The population of genetically engineered T cells comprises T cells expressing a chimeric antigen receptor (CAR) that binds CD70.